Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome

Gene

Volumn 537, Issue 2, 2014, Pages 245-252

  Lam, Uyen D P ^a   Lerchbaum, Elisabeth ^a   Schweighofer, Natascha ^a   Trummer, Olivia ^a   Eberhard, Katharina ^a   Genser, Bernd ^b,c   Pieber, Thomas R ^a   Obermayer Pietsch, Barbara ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

25(OH)D; 3'UTR; Lipids; Meprin 1A; Metabolic; Obesity; PCOS; Polymorphism; PTH; QChol HDL; SHBG; SI; SNP; TG; TT; WHR

Indexed keywords

ANDROSTENEDIONE; C PEPTIDE; GLUCOSE; INSULIN; PRASTERONE SULFATE; TRIACYLGLYCEROL;

3' UNTRANSLATED REGION; ADULT; ANDROSTENEDIONE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HIP CIRCUMFERENCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MEP 1A GENE; METABOLIC DISORDER; METABOLIC PARAMETERS; NUCLEOTIDE SEQUENCE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

25(OH)D; 25-HYDROXYVITAMIN D; 3′ UNTRANSLATED REGIONS; 3′UTR; AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE; ANALYSIS OF VARIANCE; ANOVA; ASRM; BMI; BODY MASS INDEX; DEHYDROEPIANDROSTERONE SULFATE; DEOXYRIBONUCLEIC ACID; DHEAS; DNA; EDTA; ESHRE; ETHYLENEDIAMINETETRAACETATE; EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY; FAI; FREE ANDROGEN INDEX; FREE TESTOSTERONE; FT; GNRH1; GONADOTROPIN-REALEASING HORMONE; HDL; HIGH DENSITY LIPOPROTEIN; HOMA-IR; HOMEOSTATIC MODEL ASSESSMENT-INSULIN RESISTANCE; INSULIN RESISTANCE; INTERNATIONAL SYSTEM OF UNITS; IR; LDL; LIPIDS; LOW DENSITY LIPOPROTEIN; MEPRIN 1A; METABOLIC; NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION; NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT; NCBI; NICHD; OBESITY; PARATHYROID HORMONE; PASW; PCOS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM; PREDICTIVE ANALYTICS SOFTWARE; PTH; QCHOL/HDL; QUOTIENT TOTAL CHOLESTEROL TO HDL; SEX HORMONE-BINDING GLOBULIN; SHBG; SI; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; TG; TOTAL TESTOSTERONE; TRIGLYCERIDES; TT; WAIST-TO-HIP RATIO; WHR;

3' UNTRANSLATED REGIONS; ADULT; AUSTRIA; BODY MASS INDEX; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; METALLOENDOPEPTIDASES; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84893683636     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.12.055     Document Type: Article

References (30)

1. Alvarez-Blasco F., et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 2006, 166:2081-2086.
2. Anthony P.C. Polycystic ovary syndrome: a contemporary view. J. Obstet. Gynaecol. Can. 2010, 32:423-425.
3. Banerjee S., et al. MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease. Mucosal Immunol. 2009, 2:220-231.
4. Bond J.S., Matters G.L., Banerjee S., Dusheck R.E. Meprin metalloprotease expression and regulation in kidney, intestine, urinary tract infections and cancer. FEBS Lett. 2005, 579:3317-3322.
5. Carmina E., Lobo R.A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil. Steril. 2004, 82:661-665.
6. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. 1992, 71:599-604.
7. DeUgarte C.M., Bartolucci A.A., Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 2005, 83:1454-1460.
8. Duleba A.J., Dokras A. Is PCOS an inflammatory processα. Fertil. Steril. 2012, 97:7-12.
9. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 1997, 18:774-800.
10. Escobar-Morrealé H.F., San Millán J.L. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metab. 2007, 18:266-272.
11. González F., Rote N.S., Minium J., Kirwan J.P. Evidence of proatherogenic inflammation in polycystic ovarian syndrome. Metabolism 2009, 58:954-962.
12. Heinzelmann-Schwarz V.A., et al. Low meprin α expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J. Clin. Pathol. 2007, 60:622-626.
13. Herzog C., Haun R.S., Kaushal V., Mayeux P.R., Shah S.V., Kaushal G.P. Meprin A and meprin α generate biologically functional IL-1ß from pro-IL-1ß. Biochem. Biophys. Res. Commun. 2009, 379:904-908.
14. Jiang W., Le B. Structure and expression of the human MEP1A gene encoding the alpha subunit of metalloendopeptidase meprin A. Arch. Biochem. Biophys. 2000, 379:183-187.
15. Kahal H., Atkin S.L., Sathyapalan T. Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J. Obes. 2011, 1-6.
16. Livingstone C., Collison M. Sex steroids and insulin resistance. Clin. Sci. 2002, 102:151-166.
17. Marshall J., Dunaif A. Should all women with PCOS be treated for insulin resistanceα. Fertil. Steril. 2012, 97:18-22.
18. Mathew R., et al. Meprin-α in chronic diabetes nephropathy: interaction with the renin-angiotensin axis. Am. J. Physiol. Renal Physiol. 2005, 289:911-921.
19. Nestler J.E. Insulin regulation of human ovarian androgens. Hum. Reprod. 1997, 12:53-62.
20. Norman L.P., Matters G.L., Crisman J.M., Bond J.S. Expression of meprins in health and disease. In: cell surface proteases. Curr. Top. Dev. Biol. 2003, 54:145-166.
21. Pankow K., et al. Successive action of Meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ. Res. 2007, 101:875-882.
22. Rosmann S., Hahn D., Lottaz D., Kruse M.N., Stocker W., Sterchi E.E. Activation of human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen-activating system. J. Biol. Chem. 2002, 277:40650-40658.
23. Sathyapalan T., Atkin S.L. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediat. Inflamm. 2010, 1-5.
24. Sterchi E., Stöcker W., Bond J.S. Meprins, membrane-bound and secreted astacin metalloproteinases. Mol. Aspects Med. 2008, 29:309-328.
25. Talbott E., et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J. Clin. Epidemiol. 1998, 51:415-422.
26. The Rotterdam ESHRE/ASRM-Sponsored consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19:41-47.
27. Unluturk U., Harmanci A., Kocaefe C., Yildiz B.O. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-γ. PPAR Res. 2007, 1-23.
28. Villa J.P., Bertenshaw G.P., Bylander J.E., Bond J.S. Meprin proteolytic complexes at the cell surface and in extracellular spaces. Biochem. Soc. Symp. 2003, 70:53-63.
29. Wild R.A. Dyslipidemia in PCOS. Steroids 2012, 77:295-299.
30. Winkelmann B.R., et al. Rationale and Design of the LURIC Study - A Resource for Functional Genomics, Pharmacogenomics and Long-term Prognosis of Cardiovascular Disease 2001, Ashley Publications Ltd., (ISSN 1462-2416).